Recombinant polyclonal antibodies for cancer therapy.
Although monoclonal antibodies are increasingly used for cancer therapy, remissions are only temporary due to emergence of tumor cell escape variants that are no longer affected by the antibody. The emergence of escape variants could be minimized by multi-targeting of tumor cells with polyclonal antibodies, which would also be more efficient than monoclonal antibodies at mediating effector functions for target destruction. A technology for generating recombinant polyclonal antibodies for cancer therapy has been developed based on the construction and selection of tumor-reactive Fab phage display libraries. The selected Fabs are mass-converted to full-length polyclonal antibody libraries (PCALs) of any isotype and any species. Prototypic PCALs generated against human colorectal cancer cell lines showed that libraries of diverse recombinant antibodies, enriched for reactivity to the cancer cells compared to normal human cells, can be obtained. The success of recombinant polyclonal antibodies as cancer therapeutics will depend on the ability to generate, characterize, and mass-produce PCALs with high ratios of cancer-to-normal reactivities that cross-react with many cancers of the same type.
Sharon
Jacqueline
J
Department of Pathology and Laboratory Medicine, and the Hubert H. Humphrey Cancer Research Center, Boston University School of Medicine, Boston, Massachusetts 02118, USA. jsharon@bu.edu
Liebman
Meredith A
MA
Williams
Brent R
BR
D000818:Animals; D000906:Antibodies / Q000276:immunology* / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D019151:Peptide Library; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use
D000906:Antibodies; D019151:Peptide Library; D011994:Recombinant Proteins